Altogether, our studies demonstrate persistence ERK activation in response to BRAF inhibition in BRAFwt melanoma cells, the consequences on several downstream targets, the upregulation of a wide scope of ERK-responsive genes and the physiological changes that can confer growth advantage to these cells. This evidence concerns the gene MAPK1 and melanoma.